NYSEARCA:FBT First Trust NYSE Arca Biotechnology Index Fund (FBT) Price, Holdings, & News $166.72 +0.63 (+0.38%) As of 03/27/2025 04:10 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartHoldingsOwnershipRatingsBuy This Stock About First Trust NYSE Arca Biotechnology Index Fund (NYSEARCA:FBT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get FBT alerts:Sign Up Key Stats Today's Range$166.40▼$167.7950-Day Range$166.09▼$182.1952-Week Range$140.36▼$183.60Volume8,965 shsAverage Volume25,111 shsMarket Capitalization$1.10 billionAssets Under Management$1.09 billionDividend Yield0.70%Net Expense Ratio0.56%Aggregate RatingModerate Buy ETF OverviewThe First Trust NYSE Arca Biotechnology Index Fund (FBT) is an exchange-traded fund that is based on the NYSE Arca Biotechnology index. The fund tracks an equal-weighted index of US biotechnology stocks. FBT was launched on Jun 19, 2006 and is managed by First Trust.Read More… Remove Ads First Trust NYSE Arca Biotechnology Index Fund ExpensesTypeFBTHealth Care ETFsEquity ETFsNYSEARCA ETFsAll ETFsManagement Fee0.40%0.57%0.56%0.51%0.53%Other Expenses0.16%0.30%0.49%0.57%0.52%Total Expense0.56%0.70%0.72%0.73%0.71%Fee Waiver0.00%-0.45%-0.50%-0.66%-0.55%Net Expense0.56%0.61%0.63%0.58%0.60% Receive FBT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for First Trust NYSE Arca Biotechnology Index Fund and its competitors with MarketBeat's FREE daily newsletter. Email Address FBT ETF News HeadlinesFirst Trust Announces Completion of MergersMay 6, 2024 | tmcnet.comFirst Trust NYSE Arca Biotechnology Index Fund (FBT)March 31, 2024 | finance.yahoo.comEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… They’re studying something far more alien… Something you’ve never seen before…March 28, 2025 | Paradigm Press (Ad)Closing Bell: First Trust NYSE Arca Biotechnology ETF up on Friday (FBT)January 6, 2024 | theglobeandmail.comClosing Bell: First Trust NYSE Arca Biotechnology ETF flat on Friday (FBT)January 6, 2024 | theglobeandmail.comFirst Trust Dynamic Europe Equity Income Fund Declares its Monthly Common Share Distribution of $0.07 Per Share for NovemberOctober 23, 2023 | benzinga.comSee More Headlines FBT ETF - Frequently Asked Questions How have FBT shares performed this year? First Trust NYSE Arca Biotechnology Index Fund's stock was trading at $166.21 at the start of the year. Since then, FBT shares have increased by 0.3% and is now trading at $166.72. View the best growth stocks for 2025 here. Who are First Trust NYSE Arca Biotechnology Index Fund's major shareholders? First Trust NYSE Arca Biotechnology Index Fund's top institutional investors include Bank of America Corp DE (2.89%), Wells Fargo & Company MN (2.52%), LPL Financial LLC (2.48%) and Raymond James Financial Inc. (2.21%). How do I buy shares of First Trust NYSE Arca Biotechnology Index Fund? Shares of FBT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of First Trust NYSE Arca Biotechnology Index Fund own? Based on aggregate information from My MarketBeat watchlists, some other companies that First Trust NYSE Arca Biotechnology Index Fund investors own include DiamondRock Hospitality (DRH), iShares Micro-Cap ETF (IWC), The RMR Group (RMR), Waste Connections (WCN), AUO (AUOTY), American Water Works (AWK) and Triple Flag Precious Metals (TFPM). Fund Details IssuerFirst Trust Fund NameFirst Trust NYSE Arca Biotechnology Index Fund Tax ClassificationRegulated Investment Company Stock ExchangeNYSEARCACurrent SymbolNYSEARCA:FBT Inception Date6/19/2006 Fund ManagerDaniel J. Lindquist, Jon Erickson David McGarel, RogerTestin, Stan Ueland, Chris Peterson, Erik Russo WebN/A PhoneN/AFund Focus Asset ClassEquity BenchmarkNYSE Arca Biotechnology Index CategorySector FocusHealth Care Development LevelDeveloped Markets RegionNorth America Number of Holdings31 Fund Statistics Assets Under Management$1.09 billion Average Daily Volume$20,460.20 Discount/Premium-0.06% Administrator, Advisor and Custodian AdministratorThe Bank of New York Mellon Corporation AdvisorFirst Trust Advisors L.P. CustodianThe Bank of New York Mellon Corporation DistributorFirst Trust Portfolios L.P. Transfer AgentThe Bank of New York Mellon Corporation TrusteeN/A Lead Market MakerRBC Capital Markets Options OptionableN/A Short Interest3,200 shs Miscellaneous Outstanding Shares6,600,000Beta0.70 Creation Unit50,000 Creation Fee$500.00 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.Get This Free Report Top 10 FBT HoldingsBeigene (NASDAQ:ONC)Holding Weight: 5.00%Intra-Cellular Therapies (NASDAQ:ITCI)Holding Weight: 4.62%Vertex Pharmaceuticals (NASDAQ:VRTX)Holding Weight: 4.18%Gilead Sciences (NASDAQ:GILD)Holding Weight: 4.17%Alkermes (NASDAQ:ALKS)Holding Weight: 4.08%Amgen (NASDAQ:AMGN)Holding Weight: 4.03%Halozyme Therapeutics (NASDAQ:HALO)Holding Weight: 3.98%Corcept Therapeutics (NASDAQ:CORT)Holding Weight: 3.87%Alnylam Pharmaceuticals (NASDAQ:ALNY)Holding Weight: 3.55%BioMarin Pharmaceutical (NASDAQ:BMRN)Holding Weight: 3.54%Full Holdings DetailsFBT Sector ExposureFBT Industry Exposure This page (NYSEARCA:FBT) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Wash...Paradigm Press | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredElon Musk is helping print “new gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredAI Boom Takes a Shocking Turn…A potentially historic moment for retirement Let's make the most of this market together. Crypto 101 Media | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding First Trust NYSE Arca Biotechnology Index Fund Please log in to your account or sign up in order to add this asset to your watchlist. Share First Trust NYSE Arca Biotechnology Index Fund With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.